• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Aquatech Acquires Koch's Direct Lithium Extraction Business, Integrating Li-Pro™ DLE into the PEARL™ Technology Platform

    9/16/25 5:21:00 PM ET
    $A
    $EQNR
    $SLI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Integrated oil Companies
    Energy
    Get the next $A alert in real time by email

    CANONSBURG, Pa., Sept. 16, 2025 /PRNewswire/ -- Aquatech has acquired Koch Technology Solutions' (KTS) direct lithium extraction (DLE) business, integrating the Li-Pro™ Lithium Selective Sorption (LSS) technology and extensive Li-Pro IP portfolio into the PEARL™ process technology platform.

    Aquatech and Koch logos

    The acquisition of KTS' Li-Pro LSS technology adds direct lithium extraction to Aquatech's extensive process flowsheet IP, lithium conversion and crystallization capabilities. With this addition, Aquatech's PEARL platform becomes the only commercially proven, end-to-end flowsheet solution for lithium processing. Spanning lithium extraction, purification and refining, the PEARL process technology platform delivers high-purity battery materials for electric vehicles (EV) and utility-scale electricity storage systems (ESS).

    The integration and optimization of upstream and downstream lithium processing will empower lithium resource owners with modularized process solutions at scale. This approach improves project bankability by removing process risk, accelerating project schedules and reducing the total cost of lithium production. Li-Pro LSS will be available under technology license as part of the PEARL full flowsheet licensing offerings.

    As part of the acquisition, all ongoing lithium extraction projects utilizing Li-Pro technology and associated licenses, agreements and performance guarantees will be transferred to Aquatech. This includes KTS' role in the Joint Development Agreement (JDA) with Standard Lithium Ltd. (TSXV:SLI) (NYSE:A) in the Smackover Formation, where they have completed over 12,000 operational cycles using Li-Pro technology at their demonstration plant and achieved an average lithium recovery of over 95%. It also includes a licensing agreement with Smackover Lithium, a joint venture between Standard Lithium and Equinor (NYSE:EQNR) (OSE:EQNR), for the first phase of its South West Arkansas project. The project is among the largest lithium projects in the US, with an initial phase of 22,500 tons per annum (tpa) of lithium carbonate equivalent targeting first production in 2028, with significant scope for future expansion.

    "Koch Technology Solutions has proven the Li-Pro LSS technology as a successful DLE solution, and the time has come to scale it for the market. Aquatech is uniquely placed to scale this technology and deliver it into projects as a cost competitive, end-to-end process solution, creating significant value for the lithium industry," commented Dave Dotson, President at Koch Engineered Solutions, the parent company of KTS.

    "We are confident that our legacy lithium customers will benefit from the broader offering of Aquatech. More broadly, Koch continues to maintain an active interest in the success of the technology via its investments in several key companies within the lithium minerals and lithium battery industries," said Garrett Krall, Critical Minerals & Lithium Business Leader at Koch Technology Solutions. 

     "Fragmented technology offerings increase project cost, risk and time-to-market, which has hindered the ramp-up of urgently needed critical minerals production in the Americas and Europe. Bringing Li-Pro into the PEARL technology platform solves this pressing industry need by offering the only proven full flowsheet solution that encompasses both upstream and downstream lithium processing technology," commented Venkee Sharma, Executive Chairman at Aquatech.

    Mr. Sharma continued, "We welcome the KTS Li-Pro team to Aquatech and commend them on the pioneering work done to develop Li-Pro LSS. With over 45 years of experience scaling commercially proven technologies, we are excited to evolve Li-Pro LSS both as a standalone technology offering and as part of the PEARL platform."

    About Aquatech

    Aquatech leverages innovative technology, engineering and execution leadership to solve the world's most demanding process challenges in lithium, critical minerals and industrial water. Aquatech's technology portfolio, project execution and service capabilities are grounded in a culture of performance excellence built up over four decades, with thousands of facilities using our solutions in over 60 countries.

    www.aquatech.com

    About Koch Technology Solutions

    Koch Technology Solutions (KTS) is a leader in technology licensing, delivering operating efficiency and capital productivity for licensees deploying the technologies in our portfolio. KTS partners with companies developing chemical process technologies to create attractive licensing solutions for commercial deployment, helping to bring the next generation of process technologies to the market.

    www.kochtechsolutions.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aquatech-acquires-kochs-direct-lithium-extraction-business-integrating-li-pro-dle-into-the-pearl-technology-platform-302558347.html

    SOURCE Aquatech

    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A
    $EQNR
    $SLI

    CompanyDatePrice TargetRatingAnalyst
    Agilent Technologies Inc.
    $A
    7/9/2026$135.00Hold
    Jefferies
    Agilent Technologies Inc.
    $A
    6/26/2026$155.00Outperform
    Bernstein
    Agilent Technologies Inc.
    $A
    6/11/2026$150.00Neutral
    Piper Sandler
    Agilent Technologies Inc.
    $A
    5/28/2026$145.00Neutral → Buy
    BofA Securities
    Agilent Technologies Inc.
    $A
    5/27/2026$153.00Outperform
    RBC Capital Mkts
    Equinor ASA
    $EQNR
    5/7/2026$38.00 → $40.00Hold
    TD Cowen
    Standard Lithium Ltd.
    $SLI
    4/29/2026$4.75Outperform
    Evercore ISI
    Equinor ASA
    $EQNR
    3/24/2026$40.40Underweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $A
    $EQNR
    $SLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gonsalves Rodney (Amendment)

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    10/20/23 1:07:25 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    9/29/23 4:03:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $EQNR
    $SLI
    Leadership Updates

    Live Leadership Updates

    View All

    First Atlantic Nickel & Cobalt Welcomes Former Director of the Office of Critical Minerals and Metals at the United States Department of Commerce, Gary Stanley, as Senior Strategic Advisor

    GRAND FALLS-WINDSOR, Newfoundland and Labrador, July 01, 2026 (GLOBE NEWSWIRE) -- First Atlantic Nickel & Cobalt Corp. (TSXV:FAN, OTCQB:FANCF, FSE: P210)) (the "Company" or "First Atlantic") is pleased to announce the appointment of Mr. Gary Stanley, former Director of the Office of Critical Minerals and Metals at the United States Department of Commerce, as Senior Strategic Advisor to the Company. Mr. Stanley served as the Department of Commerce’s first-ever office director dedicated to critical minerals and strategic metals, and was the lead coordinating author of the June 2019 Federal Critical Mineral Strategy, which helped establish the foundation for the current United States critical

    7/1/26 6:30:00 AM ET
    $SLI
    Major Chemicals
    Industrials

    First Atlantic Nickel & Cobalt Welcomes Former Director of the Office of Critical Minerals and Metals at the United States Department of Commerce, Gary Stanley, as Senior Strategic Advisor

    Grand Falls-Windsor, Newfoundland and Labrador--(Newsfile Corp. - June 30, 2026) - First Atlantic Nickel & Cobalt Corp. (TSXV:FAN) (OTCQB:FANCF) (FSE: P210) (the "Company" or "First Atlantic") is pleased to announce the appointment of Mr. Gary Stanley, former Director of the Office of Critical Minerals and Metals at the United States Department of Commerce, as Senior Strategic Advisor to the Company. Mr. Stanley served as the Department of Commerce's first-ever office director dedicated to critical minerals and strategic metals, and was the lead coordinating author of the June 2019 Federal Critical Mineral Strategy, which helped establish the foundation for the current United States critical

    6/30/26 7:51:00 PM ET
    $SLI
    Major Chemicals
    Industrials

    Agilent Names Michael Buckner as Chief Legal Officer

    Agilent Technologies Inc. (NYSE:A) today announced the appointment of Michael Buckner as chief legal officer, effective today. Buckner brings nearly three decades of experience as a senior global legal executive, with a proven track record of building and leading high-performing teams and deep expertise in complex transactions and regulatory environments. "We are thrilled to welcome Michael to the Agilent team," said Padraig McDonnell, Agilent president and CEO. "His experience leading global legal organizations, combined with his expertise across governance, compliance and regulatory matters, will play a key role as we continue to advance our strategy and deliver for our customers and

    5/4/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $EQNR
    $SLI
    SEC Filings

    View All

    SEC Form 6-K filed by Equinor ASA

    6-K - EQUINOR ASA (0001140625) (Filer)

    7/20/26 7:00:35 AM ET
    $EQNR
    Integrated oil Companies
    Energy

    SEC Form 6-K filed by Equinor ASA

    6-K - EQUINOR ASA (0001140625) (Filer)

    7/20/26 6:58:23 AM ET
    $EQNR
    Integrated oil Companies
    Energy

    SEC Form 6-K filed by Standard Lithium Ltd.

    6-K - STANDARD LITHIUM LTD. (0001537137) (Filer)

    7/17/26 6:43:38 PM ET
    $SLI
    Major Chemicals
    Industrials

    $A
    $EQNR
    $SLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Senior Vice President Kirkwood Jonah Prevost covered exercise/tax liability with 30 shares, decreasing direct ownership by 0.21% to 14,108 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    6/29/26 4:03:17 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    New insider Downs Timothy Charles claimed ownership of 8,872 shares (SEC Form 3)

    3 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    6/5/26 4:06:09 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Mcdonnell Padraig covered exercise/tax liability with 418 shares, decreasing direct ownership by 0.63% to 65,842 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    6/5/26 4:03:05 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $EQNR
    $SLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Agilent with a new price target

    Jefferies resumed coverage of Agilent with a rating of Hold and set a new price target of $135.00

    7/9/26 8:26:11 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bernstein resumed coverage on Agilent with a new price target

    Bernstein resumed coverage of Agilent with a rating of Outperform and set a new price target of $155.00

    6/26/26 9:17:41 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Piper Sandler initiated coverage on Agilent with a new price target

    Piper Sandler initiated coverage of Agilent with a rating of Neutral and set a new price target of $150.00

    6/11/26 8:10:17 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $EQNR
    $SLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.

    Issued on behalf of Conexeu Sciences Inc.Conexeu Sciences Inc. (NASDAQ:CNXU) is aiming its investigational CXU™ platform at the largest unclaimed frontier in injectable aesthetics: restoring real body volume at a scale today's fillers were never built to reach, a move built on the company's completed 12-month P.R.O.O.F.™ preclinical study.RENO, Nev., July 15, 2026 /CNW/ -- Equity Insider News Commentary — Every so often, a wave of demand in one corner of medicine spills over and creates an entirely new market next door. The GLP-1 weight-loss boom is doing exactly that. As roughly 1 in 8 U.S. adults have now used a GLP-1 medication and millions reshape their bodies, a second-order demand has

    7/15/26 11:01:00 AM ET
    $EQNR
    $PBF
    $TALO
    Integrated oil Companies
    Energy
    Oil & Gas Production

    Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma

    Test enables identification of patients whose tumors express PD-L1 and who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® Agilent Technologies Inc. (NYSE:A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase‑nvhy), Bristol Myers Squibb’s PD‑1‑targeted immunotherapeutic agents. PD-L1 IHC 28-8 pharmDx is approved for exclusi

    7/14/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis

    Agilent Technologies Inc. (NYSE:A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production.The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides, and conjugated therapeutics. Applications such as aggregate characterization, molecular weight confirmation and size distribution analysis remain essential for evaluating product quality, stability and performance, while drug-to-antibody

    7/8/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $EQNR
    $SLI
    Financials

    Live finance-specific insights

    View All

    Equinor's Capital Markets Day 2026

    Equinor ASA ((OSE:EQNR, NYSE:EQNR) today presents its strategy to deliver more energy, growing cash flow and superior returns. The 2026 share buy-back will be doubled to USD 3 billion, and Equinor introduces a more predictable framework for annual share buy-backs from 2027. The company aims to continue growing the quarterly cash dividend by more than 5% per share annually. Anders Opedal, president and CEO of Equinor ASA: "Demand continues to grow and Equinor is uniquely positioned to provide reliable energy. We will deliver more energy, growing cash flow and superior returns towards 2030." "Our strategy is to maximise value on the Norwegian continental shelf, deliver focused growth in int

    6/16/26 6:00:00 AM ET
    $EQNR
    Integrated oil Companies
    Energy

    Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results

    Delivers strong Q2 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS(4) guidance on continued operational momentum Second-quarter fiscal year 2026 Revenue of $1.83 billion for the second quarter ended April 30, 2026, representing growth of 10.0% reported and up 6.3% core(1) compared with the second quarter of 2025. GAAP operating margin of 21.7%; non-GAAP operating margin(2) of 26.4% expanded by 130 basis points year-over-year and 180 basis points sequentially. GAAP net income of $339 million; earnings per share (EPS) of $1.20, an increase of 60% from the second quarter of 2025. Non-GAAP net income(3) of $423 million; non-GAAP EPS(3) of $1.49, an incre

    5/27/26 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Equinor ASA: Announcement of cash dividend of 3.6041 NOK per share for fourth quarter 2025

    Equinor ASA ((OSE: EQNR, NYSE:EQNR) announced on 4 February 2026 a cash dividend per share of USD 0.39 for fourth quarter 2025. The NOK cash dividend per share is based on average USDNOK fixing rate from Norges Bank in the period plus/minus three business days from record date 15 May 2026, in total seven business days. Average Norges Bank fixing rate for this period was 9.2414. Total cash dividend for fourth quarter 2025 is consequently NOK 3.6041 per share. On 27 May 2026, the cash dividend will be paid to relevant shareholders on Oslo Børs (Oslo Stock Exchange) and to holders of American Depositary Receipts ("ADRs") on New York Stock Exchange. This information is published in accordanc

    5/21/26 1:50:00 AM ET
    $EQNR
    Integrated oil Companies
    Energy

    $A
    $EQNR
    $SLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 1:27:37 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 11:54:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/4/24 10:57:57 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials